



# UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE  
United States Patent and Trademark Office  
Address: COMMISSIONER FOR PATENTS  
P.O. Box 1450  
Alexandria, Virginia 22313-1450  
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/585,168	06/30/2006	Naohisa Kawamura	0003047USU/3019	9886
27623 7590 03/01/2010 OHLANDT, GREELEY, RUGGIERO & PERLE, LLP ONE LANDMARK SQUARE, 10TH FLOOR STAMFORD, CT 06901				
EXAMINER KENNEDY, NICOLETTA				
ART UNIT		PAPER NUMBER		
1611				
MAIL DATE		DELIVERY MODE		
03/01/2010		PAPER		

**Please find below and/or attached an Office communication concerning this application or proceeding.**

The time period for reply, if any, is set in the attached communication.

### Office Action Summary

**Application No.**

10/585,168

**Applicant(s)**

KAWAMURA ET AL.

**Examiner**

Nicoletta Kennedy

**Art Unit**

1611

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --  
**Period for Reply**

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) OR THIRTY (30) DAYS, WHICHEVER IS LONGER, FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

**Status**

- 1) ☒ Responsive to communication(s) filed on 08 September 2009.
- 2a) ☒ This action is **FINAL**. 2b) ☐ This action is non-final.
- 3) ☐ Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

**Disposition of Claims**

- 4) ☒ Claim(s) 1,3 and 5-14 is/are pending in the application.
- 4a) Of the above claim(s) \_\_\_\_\_ is/are withdrawn from consideration.
- 5) ☐ Claim(s) \_\_\_\_\_ is/are allowed.
- 6) ☒ Claim(s) 1,3 and 5-14 is/are rejected.
- 7) ☒ Claim(s) 13 is/are objected to.
- 8) ☐ Claim(s) \_\_\_\_\_ are subject to restriction and/or election requirement.

**Application Papers**

- 9) ☐ The specification is objected to by the Examiner.
- 10) ☐ The drawing(s) filed on \_\_\_\_\_ is/are: a) ☐ accepted or b) ☐ objected to by the Examiner.  
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).  
Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).
- 11) ☐ The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.

**Priority under 35 U.S.C. § 119**

- 12) ☒ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
- a) ☒ All b) ☐ Some \* c) ☐ None of:
1. ☐ Certified copies of the priority documents have been received.
  2. ☐ Certified copies of the priority documents have been received in Application No. \_\_\_\_\_.
  3. ☒ Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).

\* See the attached detailed Office action for a list of the certified copies not received.

**Attachment(s)**

- 1) ☒ Notice of References Cited (PTO-892)
- 2) ☐ Notice of Draftperson's Patent Drawing Review (PTO-948)
- 3) ☐ Information Disclosure Statement(s) (PTO/SB-08)  
Paper No(s)/Mail Date \_\_\_\_\_
- 4) ☐ Interview Summary (PTO-413)  
Paper No(s)/Mail Date \_\_\_\_\_
- 5) ☐ Notice of Informal Patent Application
- 6) ☐ Other: \_\_\_\_\_

## **DETAILED ACTION**

### ***Status of Claims***

Claims 1, 3 and 5-14 are currently pending. Claims 1, 5 and 9 are amended.  
Claims 11-14 are new and are supported by the Instant Specification.

### ***Priority***

This application, filed June 30, 2006, is a national stage entry of PCT/JP2004/019078, filed December 21, 2004 and claims foreign priority to Japanese application 2004-011384, filed January 20, 2004. , The International Bureau has provided a certified copy of the Japanese application.

### ***Withdrawn Rejections***

1. The rejection of claims 1-5 and 10 under 35 U.S.C. 103(a) as being unpatentable over Hoffman et al. in view of Spada et al. is withdrawn in view of Applicant's amendments.
2. The rejection of claims 6-8 under 35 U.S.C. 103(a) as being unpatentable over Hoffman et al. and Spada et al. in view of Burton et al. is withdrawn in view of Applicant's amendments.
3. The rejection of claim 9 under 35 U.S.C. 103(a) as being unpatentable over Hoffman et al. and Spada et al. in view of Higo et al. is withdrawn in view of Applicant's amendments.

4. The rejection of claims 1-10 on the ground of non-statutory obviousness-type double patenting is withdrawn in view of the abandonment of application 10/561,751.

***New Objection and Rejections Necessitated by Amendment***

***Claim Objections***

5. **Claim 13 is objected to because of the following informalities:** 2-ethylhexyl acrylate is misspelled as "2-ethylhexyl actylate." Appropriate correction is required.

***Claim Rejections - 35 USC § 103***

6. The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:

(a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negated by the manner in which the invention was made.

7. The factual inquiries set forth in *Graham v. John Deere Co.*, 383 U.S. 1, 148 USPQ 459 (1966), that are applied for establishing a background for determining obviousness under 35 U.S.C. 103(a) are summarized as follows:

1. Determining the scope and contents of the prior art.
  2. Ascertaining the differences between the prior art and the claims at issue.
  3. Resolving the level of ordinary skill in the pertinent art.
  4. Considering objective evidence present in the application indicating obviousness or nonobviousness.
8. This application currently names joint inventors. In considering patentability of the claims under 35 U.S.C. 103(a), the examiner presumes that the subject matter of

the various claims was commonly owned at the time any inventions covered therein were made absent any evidence to the contrary. Applicant is advised of the obligation under 37 CFR 1.56 to point out the inventor and invention dates of each claim that was not commonly owned at the time a later invention was made in order for the examiner to consider the applicability of 35 U.S.C. 103(c) and potential 35 U.S.C. 102(e), (f) or (g) prior art under 35 U.S.C. 103(a).

**9. Claims 1, 3, 5-12 and 14 are rejected under 35 U.S.C. 103(a) as being unpatentable over Hoffman et al. (US 5,254,348) (issued Oct. 19, 1993) in view of Spada et al. (US 5,185,212) (issued Feb. 9, 1993) and Wick (WO 86/06281) (pub. Nov. 6, 1986).**

Regarding claims 1, 3 and 11-12, Hoffman et al. teach a tulobuterol patch comprising a backing layer (a support) and a pressure sensitive adhesive (column 1, 1<sup>st</sup> paragraph; column 4, line 5). Tulobuterol is contained within the adhesive mix (column 2, line 55). The patch also comprises a plasticizer (column 3, line 59). However, Hoffman et al. fail to teach that the pressure sensitive adhesive is a copolymer of an acetoacetoxyalkyl (meth)acrylate and one or more vinyl monomers that are copolymerizable with the acetoacetoxyalkyl (meth)acrylate, wherein said vinyl monomer contains diacetoneacrylamide and/or tetraethyleneglycol dimethacrylate. Spada et al. and cure this deficiency.

Spada et al. teach that copolymers of acetoacetoxyalkyl (meth)acrylates and vinyl are useful as pressure-sensitive adhesives. The acetoacetoxyalkyl (meth)acrylate

may be acetoacetoxyethyl methacrylate (column 5, line 29) Spada et al. further teach a number of vinyl monomers which may be incorporated into the polymer of its composition. Spada et al. teach a pressure-sensitive adhesive composition comprising acetoacetoxyethyl methacrylate, methacrylic acid and butyl acrylate (column 13, example 2). However, Spada et al. fail to teach that the vinyl monomer contains diacetoneacrylamide and/or tetraethyleneglycol dimethacrylate.

Wick teaches a pressure-sensitive adhesive tape comprising a reinforcing monomer such as methacrylic acid and diacetone acrylamide (abstract and p. 3, lines 30-37).

It would have been prima facie obvious to a person of ordinary skill in the art at the time of the invention to have combined the teachings of Hoffman et al. with those of Spada et al. and Wick to arrive at the instant invention. One would have been motivated to substitute diacetone acrylamide for methacrylic acid in the example taught by Spada et al. because Wick teaches that both are reinforcing monomers used in pressure-sensitive adhesives. One would have been motivated to use the pressure-sensitive adhesive of Spada et al. and Wick in the transdermal patch of Hoffman et al. because the pressure-sensitive adhesive of Spada et al. and Wick is well known in the art and may be used in a transdermal patch with predictable, expected results.

Regarding claims 5-7, Wick teaches that isopropyl myristate is used in the pressure-sensitive adhesive tape formulation (p. 15, line 29).

Regarding claim 8, Wick teaches that ethyl oleate, a plasticizer, is present at 12% by weight of the formulation (p. 15, line 24).

Regarding claim 9, Hoffman et al. teach that 0.96 grams tulobuterol base are added to 60 grams of a pressure-sensitive adhesive solution, resulting in tulobuterol being present at 1.6% by weight (column 4, example 1). The solution is stirred until completely dissolved (column 4, example 1).

Regarding claim 10, no water is present in the pressure-sensitive adhesive taught by the combination of Hoffman et al., Spada et al. and Wick (Spada et al., column 14, example 2).

Regarding claim 14, Spada et al. teach that the acetoacetoxyethyl methacrylate is present at 2.0% (column 13, example 2). MPEP 2144.05 states that "where the general conditions of a claim are disclosed in the prior art, it is not inventive to discover the optimum or workable ranges by routine experimentation" quoting *In re Aller*, 220 F.2d 454, 456, 105 USPQ 233, 235 (CCPA 1955). Spada et al. teach that increasing the amount of acetoacetoxyethyl methacrylate results in increased shear and it would have been prima facie obvious to a person of ordinary skill in the art to manipulate the amount of acetoacetoxyethyl methacrylate to find optimum or workable ranges.

**10. Claim 13 is rejected under 35 U.S.C. 103(a) as being unpatentable over Hoffman et al. (US 5,254,348) (issued Oct. 19, 1993), Spada et al. (US 5,185,212) (issued Feb. 9, 1993) and Wick (WO 86/06281) (pub. Nov. 6, 1986) as applied to claims 1, 3, 5-12 and 14 above, and further in view of Kamiyama (US 6,632,906) (issued Oct. 14, 2003).**

The combination of Hoffman et al., Spada et al. and Wick teach a tulobuterol adhesive patch with a pressure-sensitive adhesive comprising 2-acetoacetoxyethyl methacrylate, butyl methacrylate, and diacetone acrylamide. However, they fail to teach that the pressure-sensitive adhesive comprises 2-acetoacetoxyethyl methacrylate, diacetone acrylamide, tetraethyleneglycol dimethacrylate, 2-ethylhexyl acrylate and methylmethacrylate. Kamiyama cures this deficiency.

Kamiyama teaches an adhesive material suitable as a bioadhesive having good cohesion and low dermal irritation wherein 2-ethylhexyl acrylate, methyl methacrylate, butyl acrylate, diacetone acrylamide and tetraethyleneglycol dimethacrylate may be used to form adhesive of the invention (column 11, example 2, table 1 and table 1a). MPEP 2144.06 states that "[i]t is *prima facie* obvious to combine two compositions each of which is taught by the prior art to be useful for the same purpose, in order to form a third composition to be used for the very same purpose.... [T]he idea of combining them flows logically from their having been individually taught in the prior art" quoting *In re Kerkhoven*, 626 F.2d 846, 850, 205 USPQ 1069, 1072 (CCPA 1980). In the instant case, Hoffman et al., Spada et al. and Wick teach a tulobuterol adhesive patch with a pressure-sensitive adhesive comprising 2-acetoacetoxyethyl methacrylate, butyl methacrylate, and diacetone acrylamide.

It would have been *prima facie* obvious to a person of ordinary skill in the art at the time of the invention to have combine known adhesive copolymer components together to make a composition to be used for the very same purpose, as an adhesive material. One would have been motivated to do so because Spada et al. and Wick



teach a basic pressure-sensitive adhesive composition and Kamiyama teach several more monomers that may be incorporated into an adhesive composition to result in good cohesion and low dermal irritation.

### ***Response to Arguments***

11. Applicant's arguments with respect to claims 1, 3 and 5-10 have been considered but are moot in view of the new ground(s) of rejection.

### ***Conclusion***

No claims are allowable.

Applicant's amendment necessitated the new ground(s) of rejection presented in this Office action. Accordingly, **THIS ACTION IS MADE FINAL**. See MPEP § 706.07(a). Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a).

A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any extension fee pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the date of this final action.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Nicoletta Kennedy whose telephone number is (571)270-1343. The examiner can normally be reached on Monday through Thursday 8:15 to 6:45.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Sharmila Gollamudi Landau can be reached on 571-272-0614. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see <http://pair-direct.uspto.gov>. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.

/N. K./  
Examiner, Art Unit 1611

/Sharmila Gollamudi Landau/  
Supervisory Patent Examiner, Art Unit 1611